> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-159/
- Published: 2017-12-03T12:00:00.000Z
- Updated: 2026-09-14T23:04:41.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5140258

[**Panel to Review Ciprofloxacin Dispersion for Inhalation NDA**](https://www.fdaweb.com/panel-to-review-ciprofloxacin-dispersion-for-inhalation-nda/)  
*Federal Register* notice: FDA announces a 1/11/2018 Antimicrobial Drugs Advisory Committee meeting. to review an NDA for ciprofloxacin dispersion for inhalation. 12/01/2017

[**Meticorten Not Withdrawn Due to Safety/Effectiveness: FDA**](https://www.fdaweb.com/meticorten-not-withdrawn-due-to-safety-effectiveness-fda/)  
*Federal Register* notice: FDA determines that Schering’s Meticorten (prednisone) tablets were not withdrawn from sale for reasons of safety or effectiveness. 12/01/2017

[**68 ANDA Approvals Withdrawn: FDA**](https://www.fdaweb.com/68-anda-approvals-withdrawn-fda/)  
*Federal Register* notice: FDA announces the withdrawal of 68 ANDAs from multiple applicants. 12/01/2017

[**FDA Proposes 510(k) Exemption for Surgical Apparel**](https://www.fdaweb.com/fda-proposes-510-k-exemption-for-surgical-apparel/)  
*Federal Register* notice: FDA announces its intent to exempt certain subtypes of surgical apparel from premarket notification requirements, subject to conditions and limitations. 11/30/2017

[**Draft Guide on Dual 510(k) and CLIA Waiver**](https://www.fdaweb.com/draft-guide-on-dual-510-k-and-clia-waiver/)  
*Federal Register* notice: FDA makes available a draft guidance entitled “Recommendations for Dual 510(k) and Clinical Laboratory Improvement Amendments (CLIA) Waiver by Application Studies.” 11/30/2017

[**Public Hearing on Evaluating Nicotine Replacement Products**](https://www.fdaweb.com/public-hearing-on-evaluating-nicotine-replacement-products/)  
*Federal Register* notice: FDA announces a 1/26/2018 public hearing on its approach to evaluating the safety and efficacy of nicotine replacement therapy products, including how they should be used and labeled. 11/30/2017

[**Regulatory Review Period Determined for Xuriden**](https://www.fdaweb.com/regulatory-review-period-determined-for-xuriden/)  
*Federal Register* notice: FDA determines the regulatory review period for patent extension purposes for Wellstat Therapeutics’ Xuriden (uridine triacetate), indicated for treating hereditary orotic aciduria. 11/29/2017

[**Regulatory Review Period Determined for Veltassa**](https://www.fdaweb.com/regulatory-review-period-determined-for-veltassa/)  
*Federal Register* notice: FDA determines the regulatory review period for patent extension purposes for Relypsa’s Veltassa (patiromer sorbitex calcium), indicated for treating hyperkalemia. 11/29/2017